47 results about "Diagnostic screening" patented technology

The invention relates to a quantitative diagnosis method, device and equipment for psychological abnormal diseases, and relates to the technical field of large language models.The method comprises the steps that in the interrogation interaction process with a target object, an input voice set of the target object is continuously obtained, and each piece of voice information in the input voice set is obtained; the method comprises the following steps of: performing care type common-situation output based on a care type reply requirement through a psychologist model, extracting a scale question related to evaluation from a preset other-evaluation mental scale through a preset psychologist model, and obtaining a question and answer data pair set according to a question question of a previous round of dialogue and an input voice set, and performing multi-modal quantitative scoring processing on the set according to the question and answer data to obtain an inquiry result of the target object after multiple rounds of cumulative scoring. Visibly, the analysis and quantification are carried out by combining the scale and the diagnosis dialogue data of the patient to extract the key emotion index, so that rapid diagnosis and screening of psychological abnormal diseases such as depression can be objectively, accurately and efficiently assisted.

A biofluid-based diagnostic screening system and associated methods are disclosed for screening a volume of biofluid of a patient for an at least one medical condition. In at least one embodiment, the system provides a lateral flow test strip, a test housing sized and configured for removably receiving the test strip therewithin, and a user application residing locally in memory on an imaging device and configured for screening a volume of biofluid of a patient, as deposited on the test strip, for an at least one medical condition.

Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and / or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and / or predicting women who are "at risk" for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a cervicovaginal lavage (CVL) or vaginal swab sample from a patient and producing a profile of at least five or more biomarkers from the collected sample.

The invention relates to the technical field of biological medicines, in particular to FcRL2 as a serum marker or cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. The FcRL2 protein is one of receptor superfamily members, Fc receptor-like glycoproteins, and is related to immune response regulation and immune cell functions. According to the invention, the concentration of the FcRL2 protein in serum or cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, evaluation of nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. Compared with the prior art, the FcRL2 not only has high sensitivity, but also can diagnose the neurosyphilis through noninvasive serum detection, and is beneficial to diagnosis and management of the neurosyphilis in community hospitals and local hospitals.

The invention relates to the technical field of biological detection, in particular to a nucleic acid sequence combination for detecting cervical cell gene methylation, a kit and application. The nucleic acid sequence combination for detecting the methylation of the cervical cell gene, provided by the invention, can specifically detect the methylation of ABCC9 and LINC00605 genes of an endometrial cancer cervical exfoliated cell sample, which are different from those of a healthy human cervical exfoliated cell sample, and the kit for detecting the methylation of the cervical cell gene, which is prepared by utilizing the nucleic acid sequence combination, can be used for detecting the methylation of the cervical cell gene. The kit is applied to diagnosis / screening of endometrial cancer, has relatively high detection sensitivity and specificity on stage I and stage II endometrial cancer, is simple to operate and beneficial to popularization and application, and noninvasive material drawing is realized.

Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and / or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring protein biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and / or predicting women that are “at risk” for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a sample (e.g., CVL, vaginal swabs, or secretions) from a patient and producing a profile of at least five or more protein biomarkers from the collected sample.

The invention relates to the technical field of biological medicines, in particular to a CLM-6 protein (CMRF35-l ike molle 6) as a serum marker or cerebrospinal fluid marker for early diagnosis, screening and typing detection of a neurosyphilis patient. According to the invention, the concentration of CLM-6 protein in cerebrospinal fluid or serum is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, nerve injury degree evaluation and the like; the index can be independently used or used as a main reference index to be combined with other indexes to finish the diagnosis screening and typing of the neurosyphilis and the evaluation of nerve injury. Compared with the prior art, the CLM-6 not only has higher sensitivity, but also can realize noninvasive serum detection on the neurosyphilis, is convenient to detect, and is more beneficial to early diagnosis and management of the neurosyphilis in community hospitals and local hospitals.

The invention belongs to the technical field of biology, and particularly relates to a Parkinson's disease diagnosis kit based on a peripheral red blood cell alpha-synuclein RT-QuIC technology and application of the Parkinson's disease diagnosis kit. The Parkinson's disease diagnostic kit based on the peripheral red blood cell alpha-synuclein RT-QuIC technology comprises a substrate protein, a reaction reagent, a negative reference substance and a positive reference substance, and a sample is selected from red blood cells in blood. The RT-QuIC technology is applied to diagnosis of neurodegenerative diseases, particularly, the sowing activity of pathological alpha-Syn protein is detected in blood red blood cell samples of PD patients of Chinese population for the first time, and the kit has extremely high sensitivity and specificity and provides important reference value for diagnosis and screening of PD. The invention provides a rapid, efficient and accurate diagnostic kit for diagnosis of Parkinson's disease, the kit can be used for accurately detecting Parkinson's disease patients and healthy control, and powerful technical support is provided for clinical diagnosis of the Parkinson's disease patients.

The invention relates to the technical field of biological medicine, in particular to application of cerebrospinal fluid CTSC protein as a marker in preparation of neurosyphilis or nerve injury diagnosis products. The CTSC protein is also called Dipetidyl petidease 1, and according to the research conclusion of the invention, the CTSC protein can be used as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. By measuring the concentration of CTSC protein in cerebrospinal fluid, the concentration is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, and nerve injury degree evaluation. The index can be independently used or used as a main reference index to be combined with other indexes for completing diagnosis screening, typing and nerve injury evaluation of the neurosyphilis, and the index has the advantages of being good in sensitivity, high in specificity and the like.

The invention belongs to the technical field of biomedicine, and particularly relates to a gene methylation marker and application thereof. The invention discloses the ELTD1 gene methylation marker for the first time, the ELTD1 gene methylation marker can be used for diagnosis, screening, monitoring, curative effect evaluation or prognosis evaluation of the lung cancer, the sensitivity is high, and the detection rate of the lung cancer is greatly improved.

The application discloses an image sharpening and enhancing method in cataract diagnosis screening, belongs to the field of image enhancement, and aims to improve the quality of cataract diagnosis screening images. The method first collects images to construct a cataract diagnosis screening image dataset, then extracts optimal illumination components and reflection components by using an interactive separation module based on structure perception through structure response distillation and a joint optimization target strategy, and then enhances the illumination components by using an illumination component structure adjustment module and improves the details of the reflection components by using a reflection component high-frequency residual enhancement module, integrates all the modules to construct an image enhancement model, and finally inputs the dataset into the model to output high-resolution cataract diagnosis screening images.

The invention provides a method for pooling samples prior to a diagnostic screen for a non-infectious disease. The method includes pooling only a portion of the obtained samples and storing the other portion for later use. Pooling samples represents a more time and cost-effective way to perform diagnostic screening.

The invention relates to the field of gene detection, in particular to a molecular marker for diagnosis, screening and risk prediction of early lung cancer. According to the present invention, the substance specifically binding to SPATA18 is selected from one or more of an antibody, a primer or a probe; the substance specifically binding to SPATA18 provided by the invention can realize diagnosis, screening and risk prediction of early lung adenocarcinoma, and fills the blank of risk and prognosis prediction of early non-invasive adenocarcinoma clinically; abnormities on the molecular level can be detected in the early stage of cancer development, and earlier intervention and treatment opportunities can be provided, so that the treatment success rate is increased; according to the method, the number of targets is relatively small, the stability is theoretically higher than that of other multi-target detection after the sample amount is increased, more accurate cancer risk assessment can be provided, the cancer progress probability of a patient can be better predicted, and making of a more accurate treatment plan is facilitated.

The present invention refers an in vitro method for inducing differentiation of human pluripotent stem cells (hPSCs) generating hindbrain neurons and compositions thereof. The invention also refers to the hindbrain neurons and compositions thereof for use in diagnostic screening and for use in the prevention and / or treatment of neurological disorders.

The invention provides a method for sample pooling prior to diagnostic screening for non-infectious diseases. The method comprises pooling only a portion of the obtained sample and storing another portion for later use. Sample pooling represents a more time and cost efficient way of performing diagnostic screening.

The invention relates to an occupational pneumoconiosis diagnosis and screening method. The method comprises the following steps: (1) data preparation; (2) carrying out graying processing on the collected X-ray film image; (3) extracting texture features from the preprocessed image by using a gray level co-occurrence matrix (GLCM) algorithm; (4) carrying out screening and dimension reduction processing on the extracted GLCM features; (5) constructing a CNN model, and upgrading and optimizing a residual network architecture; (6) training the CNN model by using the marked data set, and evaluating the performance of the model by using a cross validation method; and (7) inputting the trained CNN model for diagnosis screening. According to the method, gray-level co-occurrence matrix feature extraction is combined with the CNN model, a residual network architecture is upgraded and optimized for diagnosis and screening of occupational pneumoconiosis, the identification precision and the operation speed are improved, and the method is very suitable for research of pneumoconiosis.

The invention relates to the technical field of biological medicines, in particular to application of cerebrospinal fluid CD38 protein and a specific antibody thereof in preparation of neurosyphilis or nerve injury diagnosis products. By measuring the concentration of CD38 protein in cerebrospinal fluid, the concentration is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, nerve injury degree evaluation and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of syphilis. Compared with the prior art, the marker has the advantages of good sensitivity, high specificity and the like, and is beneficial to diagnosis and management of neurosyphilis.

The invention provides methods for assessment of tumor biomarkers using target-enriched multiplexed parallel analysis. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with DNA samples from a patient, such as a tissue biopsy or plasma sample (liquid biopsy), for detection of the presence of tumor biomarkers, e.g., for purposes of diagnosis, screening, therapy selection and / or treatment monitoring. Kits for carrying out the methods of the invention are also provided.

The present invention relates to the field of biomedical technology, and specifically to the use of cerebrospinal fluid CD38 protein and its specific antibody in the preparation of neurosyphilis or nerve damage diagnosis products. By measuring the concentration of CD38 protein in cerebrospinal fluid, the concentration is used as an indicator for early diagnosis of neurosyphilis, symptomatic neurosyphilis, asymptomatic neurosyphilis, typing detection of neurosyphilis and latent syphilis, and evaluation of the degree of nerve damage. The indicator can be used alone or as a main reference indicator in combination with other indicators to complete the diagnostic screening, typing and nerve damage evaluation of syphilis. Compared with the existing technology, this marker has the advantages of good sensitivity and high specificity, which is conducive to the diagnosis and management of neurosyphilis.

The invention discloses a pathological section diagnosis screening analysis method based on a deep neural network, and the method comprises the steps: S1, obtaining the digital image data of a pathological section, and carrying out the preprocessing, and forming an image data set; s2, constructing a three-dimensional space-time Transform network model, obtaining feature images in a space-time dimension, and forming an image feature set; s3, model parameters pre-trained on the large-scale image data set are migrated to the constructed three-dimensional space-time Transform network model through migration learning, and the model is optimized; s4, training the fine-tuned model by using the labeled pathological section image data set; and S5, inputting a pathological section image to be diagnosed and screened into the trained model, and outputting a diagnosis result. According to the method, the diagnosis result is rapidly and accurately output and visually displayed, and the pathological diagnosis efficiency and accuracy are improved.

The present invention relates to the field of biomedical technology, and specifically to the use of cerebrospinal fluid CTSC protein as a marker in the preparation of neurosyphilis or nerve damage diagnosis products. CTSC protein is also called Dipeptidyl peptidase 1. According to the research conclusions of the present invention, it can be used as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. By measuring the concentration of CTSC protein in cerebrospinal fluid, the concentration is used as an indicator for early diagnosis of neurosyphilis, symptomatic neurosyphilis, asymptomatic neurosyphilis, typing detection of neurosyphilis and latent syphilis, and evaluation of the degree of nerve damage. The indicator can be used alone or as a main reference indicator in combination with other indicators to complete the diagnosis, screening, typing and nerve damage evaluation of neurosyphilis. The indicator has the advantages of good sensitivity and high specificity.

This invention discloses an anti-CD5 protein nanobody and its applications, relating to the field of nanobody biosynthesis technology. Utilizing a camel-derived nanobody library and targeting mouse CD5 protein, this invention employs phage display technology for in vitro enrichment and panning. Camel-derived nanobody sequences targeting CD5 protein are obtained through monoclonal high-throughput ELISA screening. These five nanobody sequences can be used to detect CD5 protein expression, for the diagnosis and screening of related tumors, and also for the preparation of drugs to treat related tumors.

The present invention relates to the field of disease diagnosis, and specifically to the use of Rv1860 protein, RV3881c protein, Rv2031c protein and Rv3803c protein in the preparation of diagnostics for active pulmonary tuberculosis infection. The present invention provides a product for detecting the levels of anti-Rv1860 antibodies, anti-RV3881c antibodies, anti-Rv2031c antibodies and anti-Rv3803c antibodies in serum for use in the preparation of products for identification, diagnosis, auxiliary diagnosis, screening and / or auxiliary screening of patients with active pulmonary tuberculosis infection. Experiments have shown that a biomarker combination containing four antigens can effectively screen patients with active pulmonary tuberculosis infection.

The application discloses a radial multilayer microneedle sensing system and method for single follicular unit microenvironment analysis, and belongs to the field of skin appendage detection and biological micro-electro-mechanical systems. The system comprises a positioning hole integrated with an optical collimation unit, concentric ring microneedles with a length ratio within a certain range, ring compression protruding structures between the microneedles, a differential negative pressure sampling module and a detection electrode modified with an aptamer probe, which can accurately position the follicle, perform layered puncture, construct a hydraulic barrier to prevent cross-flow, isolate and extract interstitial fluid between deep and shallow layers and target detection of disease markers such as androgen alopecia. The method comprises the steps of optical targeting positioning, compression sealing puncture, differential sampling, in-situ detection and gradient index calculation. The application can improve the spatial detection resolution of the markers, solve the problems of signal dilution and subcutaneous cross-flow, and provide a quantitative tool for follicular pathological research and drug non-diagnostic screening.

A system for diagnostic screening of a chronic disease includes a test matrix and a user device. The test matrix has a calibration surface including one or more calibration elements and one or more reagents. The user device has image capturing and processing capabilities configured to capture an image and a processor configured to locate, based on the plurality of calibration elements, the test matrix in the image, determine if the test matrix indicates the presence of the chronic disease by comparing a detected contrast of the one or more reagents with the test matrix to an augmented reality trained database, and generate a screening report based on the determination.

The invention relates to the technical field of biomarkers, in particular to a kit for diagnosing / screening endometrial cancer. The kit provided by the invention is applied to early diagnosis / screening of endometrial cancer, can specifically detect methylation of the LINC01551 gene and the C5orf38 gene in an endometrial cancer cervical exfoliated cell sample, has relatively high detection sensitivity and specificity, and provides a new way for early diagnosis / screening of clinical endometrial cancer.

An integrated device and method are disclosed for single-step extraction and affinity capture of analytes from dried biological sample carriers. The device defines an internal cavity configured to fully receive a sample carrier comprising a dried biological sample, such as a dried blood spot. Multiple analyte-specific capture elements are immobilized on a surface within the cavity. Upon introduction of an extraction buffer, analytes are released from the dried sample and concurrently captured by the immobilized capture elements within the same device, eliminating intermediate elution, transfer, or washing steps. Continuous depletion of free analyte within the capture zone promotes further analyte release from the dried sample, enabling efficient equilibrium-driven extraction. The device is compatible with immunoassay and other affinity-based detection formats and supports proteins, nucleic acids, and small-molecule analytes. The disclosed device reduces processing time, handling complexity, and sample loss, and is suitable for diagnostic, screening, and monitoring applications.

The present invention provides systems, instruments, and methods for determining genetic or molecular distortions in a biological sample from an organism. Biological samples including free DNA fragments are analyzed to identify imbalances present in chromosomal regions, e.g., due to tumor chromosome deletion and / or amplification. Multiple loci are used for analysis of individual chromosomal regions. Such imbalances can then be used to diagnose (screen) cancer as well as prognosis of cancer patients, or to detect a patient's pre-exacerbation health status or to monitor changes in a patient's pre-exacerbation health status. Diagnosis, screening, prognosis, and monitoring can be provided using the severity of genomic imbalances, as well as the number of regions of imbalance. Systematic analysis of non-overlapping chromosome segments can provide a universal cancer screening means. Furthermore, the patient can be examined at different points in time to track one or more chromosomal regions and the severity of each of the numerous chromosomal regions and the number of chromosomal regions exhibiting chromosomal aberrations, therefore, cancer screening, prognosis diagnosis and lesion process monitoring (for example, after treatment) can be carried out.

The invention discloses a biomarker combination, application, a product and a system for detecting local progression stage gastric cancer, and relates to the technical field of biological medicines. The biomarker combination for diagnosis, screening, illness state monitoring and / or drug curative effect monitoring of the local progression stage gastric cancer comprises the following proteins: SRI, SMARCA5, TPD52, PLBD1, PDLIM7, COL18A1, ACTR3, ALDH1A1, EHD2, ARF5, DNPEP, OGFR, PBXIP1, GOT1, SNW1, PRKAR1A, DCTN2, TMEM109, ANPEP and MOV10. According to the invention, a 20-panel proteome prediction model is constructed for the first time, and compared with PDL1 expression, the 20-panel proteome prediction model has better capability of predicting treatment response crowds. Compared with PDL1 expression which is most commonly used for judging the curative effect of gastric cancer immunotherapy clinically at present, the sensitivity, the specificity, the AUC and the like of the 20-Panel proteome for predicting pathological response people are obviously improved. The method is beneficial for efficiently and accurately predicting and screening sensitive people who receive neoadjuvant chemotherapy and immunotherapy on the gastric cancer in the local development stage before treatment, and the most suitable treatment scheme is selected.

The present invention discloses an auxiliary screening system, application method and model of cervical liquid-based thin-layer cytology, wherein the system comprises: a collection module for collecting electronic images of massively scanned cervical liquid-based thin-layer cytology; a labeling module for identifying abnormal cells in each electronic image, outlining abnormal cells in the electronic image, and adding real labels to the abnormal cells; a training module for training the real labels corresponding to the abnormal cells to obtain a cell-level diagnostic model, and training the sheet-level diagnostic model using the information output by the cell-level diagnostic model; a diagnosis and screening module for diagnosing and screening cells using the sheet-level diagnostic model; and a diagnostic efficiency module for respectively obtaining comparative screening results, auxiliary screening results and diagnostic screening results, and respectively calculating the diagnostic efficiency of each result. The present invention can increase the recognition ability of the model, and can also further improve the recognition ability of the model, and improve the recognition accuracy and efficiency.